Morgan Stanley analyst Stephen Byrd suggested buying power companies he thought could benefit from the AI boom.

Individualized cancer vaccines and antibody-drug conjugates will be among the dominant biotech innovations in cancer next ...

In recent years, there has been a noted increase in the rates of chronic disease, as well as a growth in the number of ...

The stock's fall snapped a four-day winning streak.

The Morgan Stanley executive is retiring to run a foundation she started that aims to bring more young women into wealth ...

They are some of the most important technologists on Wall Street. Here's an inside look at what they do and what it takes to ...

We recently compiled a list of the 10 AI News You Can’t Miss. In this article, we are going to take a look at where Broadcom ...

The Australian central bank's rate trajectory and its effect on inflation will decide if Australian bank shares can eke out ...

Stay cautious of market momentum in 2025. Stock picking will be key for value opportunities in overlooked sectors like real ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Morgan Stanley maintains a solid balance sheet, with assets reaching $1.26t and shareholder equity rising to $103.6b. Read ...

MS stock gains 32.4% this year. With the revival of global M&As, read on to know how 2025 will be for the stock and what ...